JP2022516557A5 - - Google Patents
Info
- Publication number
- JP2022516557A5 JP2022516557A5 JP2021538982A JP2021538982A JP2022516557A5 JP 2022516557 A5 JP2022516557 A5 JP 2022516557A5 JP 2021538982 A JP2021538982 A JP 2021538982A JP 2021538982 A JP2021538982 A JP 2021538982A JP 2022516557 A5 JP2022516557 A5 JP 2022516557A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding domain
- domain binds
- cancer
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024185692A JP2025013911A (ja) | 2019-01-07 | 2024-10-22 | 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789075P | 2019-01-07 | 2019-01-07 | |
| US62/789,075 | 2019-01-07 | ||
| PCT/US2020/012296 WO2020146221A1 (en) | 2019-01-07 | 2020-01-06 | Polypeptides comprising modified il-2 polypeptides and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024185692A Division JP2025013911A (ja) | 2019-01-07 | 2024-10-22 | 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022516557A JP2022516557A (ja) | 2022-02-28 |
| JP2022516557A5 true JP2022516557A5 (https=) | 2023-01-19 |
| JP7594161B2 JP7594161B2 (ja) | 2024-12-04 |
Family
ID=69374426
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021538982A Active JP7594161B2 (ja) | 2019-01-07 | 2020-01-06 | 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用 |
| JP2024185692A Pending JP2025013911A (ja) | 2019-01-07 | 2024-10-22 | 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024185692A Pending JP2025013911A (ja) | 2019-01-07 | 2024-10-22 | 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220089667A1 (https=) |
| EP (1) | EP3908596A1 (https=) |
| JP (2) | JP7594161B2 (https=) |
| KR (1) | KR20210113265A (https=) |
| CN (1) | CN113924311A (https=) |
| AR (1) | AR117770A1 (https=) |
| AU (2) | AU2020206672B2 (https=) |
| BR (1) | BR112021012294A2 (https=) |
| CA (1) | CA3125529A1 (https=) |
| CL (1) | CL2021001779A1 (https=) |
| IL (1) | IL284633A (https=) |
| MX (1) | MX2021008147A (https=) |
| SG (1) | SG11202106700WA (https=) |
| TW (1) | TWI874345B (https=) |
| WO (1) | WO2020146221A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240141853A (ko) | 2017-08-03 | 2024-09-27 | 신톡스, 인크. | 자가면역 질환의 치료를 위한 사이토카인 접합체 |
| IL276365B2 (en) | 2018-02-01 | 2023-10-01 | Nkmax Co Ltd | A method for the production of natural killer cells and a preparation for cancer treatment |
| SG11202102930YA (en) | 2018-11-08 | 2021-04-29 | Synthorx Inc | Interleukin 10 conjugates and uses thereof |
| EP3923974A4 (en) | 2019-02-06 | 2023-02-08 | Synthorx, Inc. | IL-2 CONJUGATES AND METHODS OF USE THEREOF |
| EP4017540A1 (en) | 2019-08-23 | 2022-06-29 | Synthorx, Inc. | Il-15 conjugates and uses thereof |
| US12234271B2 (en) | 2019-09-10 | 2025-02-25 | Synthorx, Inc. | Il-2 conjugates and methods of use to treat autoimmune diseases |
| EP4174088A4 (en) * | 2020-06-30 | 2024-01-24 | GI Innovation, Inc. | FUSION PROTEIN COMPRISING AN ANTI-LAG-3 AND IL-2 ANTIBODY AND USE THEREOF |
| US20230235005A1 (en) * | 2020-07-02 | 2023-07-27 | Inhibrx, Inc. | Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof |
| KR20230112632A (ko) | 2020-10-23 | 2023-07-27 | 애셔 바이오테라퓨틱스, 인크. | 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합 |
| US20220144956A1 (en) * | 2020-11-06 | 2022-05-12 | Xencor, Inc. | HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII |
| WO2022115865A2 (en) | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| KR20230129983A (ko) * | 2020-12-09 | 2023-09-11 | 애셔 바이오테라퓨틱스, 인크. | 조작된 세포 요법을 위한 표적화된 사이토카인 구축물 |
| CN112979782B (zh) * | 2021-03-08 | 2023-07-18 | 深圳市乐土生物医药有限公司 | 一种多肽及其用途 |
| JP2024512714A (ja) * | 2021-03-31 | 2024-03-19 | アンウィタ バイオサイエンシス， インク． | 融合タンパク質、医薬組成物、及び治療適用 |
| EP4373854A1 (en) * | 2021-07-20 | 2024-05-29 | Inhibrx, Inc. | Cd8-binding polypeptides and uses thereof |
| TW202309102A (zh) * | 2021-07-20 | 2023-03-01 | 美商英伊布里克斯公司 | 靶向cd8之經修飾il-2多肽及其用途 |
| US20240376198A1 (en) * | 2021-08-30 | 2024-11-14 | Inhibrx, Inc. | NKp46-Targeted Modified IL-2 Polypeptides and Uses Thereof |
| JP2024534838A (ja) * | 2021-08-30 | 2024-09-26 | インヒブルクス インコーポレイテッド | ＮＫｐ４６結合ポリペプチド及びその使用 |
| EP4405487A4 (en) * | 2021-09-26 | 2025-12-03 | Wuxi Biologics Ireland Ltd | IL-2 VARIANTS AND THEIR FUSING PROTEINS |
| WO2023133393A1 (en) * | 2022-01-05 | 2023-07-13 | Inhibrx, Inc. | Gamma delta t-cell-targeted modified il-2 polypeptides and uses thereof |
| WO2024026449A2 (en) * | 2022-07-28 | 2024-02-01 | Proviva Therapeutics (Hong Kong) Limited | Il-2 procytokine antibody fusion proteins |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
| DK1454138T3 (da) * | 2001-12-04 | 2012-02-13 | Merck Patent Gmbh | Immunocytokiner med moduleret selektivitet |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| CA2541651C (en) | 2003-10-22 | 2011-05-24 | Keck Graduate Institute | Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy |
| CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
| US20060234205A1 (en) * | 2004-03-05 | 2006-10-19 | Chiron Corporation | In vitro test system for predicting patient tolerability of therapeutic agents |
| EP1740615B1 (en) | 2004-03-31 | 2014-11-05 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| CN102101885B (zh) * | 2010-09-01 | 2013-06-05 | 南京发士达生物科技有限公司 | 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途 |
| SG192673A1 (en) * | 2011-02-10 | 2013-09-30 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
| WO2013180200A1 (ja) * | 2012-05-30 | 2013-12-05 | 中外製薬株式会社 | 標的組織特異的抗原結合分子 |
| PT3102595T (pt) * | 2014-02-06 | 2019-01-11 | Hoffmann La Roche | Proteínas de fusão de interleucina-2 e suas utilizações |
| WO2017121758A1 (en) * | 2016-01-11 | 2017-07-20 | Universität Zürich | Combination therapy comprising a superagonistic antibody against interleukin-2 and a checkpoint blockade agent |
| JP7422480B2 (ja) * | 2016-05-04 | 2024-01-26 | アムジエン・インコーポレーテツド | 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質 |
| US20200010528A1 (en) * | 2017-03-15 | 2020-01-09 | Cue Biopharma, Inc. | Methods for modulating an immune response |
| JP7148539B2 (ja) * | 2017-04-03 | 2022-10-05 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 免疫抱合体 |
| EP4516809A3 (en) * | 2017-04-05 | 2025-09-03 | F. Hoffmann-La Roche AG | Bispecific antibodies specifically binding to pd1 and lag3 |
| US10676516B2 (en) * | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| CN111201035A (zh) * | 2017-06-19 | 2020-05-26 | 梅迪塞纳医疗股份有限公司 | Il-2超激动剂、激动剂及其融合体的用途和方法 |
-
2020
- 2020-01-06 SG SG11202106700WA patent/SG11202106700WA/en unknown
- 2020-01-06 CN CN202080018011.6A patent/CN113924311A/zh active Pending
- 2020-01-06 JP JP2021538982A patent/JP7594161B2/ja active Active
- 2020-01-06 WO PCT/US2020/012296 patent/WO2020146221A1/en not_active Ceased
- 2020-01-06 TW TW109100336A patent/TWI874345B/zh active
- 2020-01-06 EP EP20702547.9A patent/EP3908596A1/en active Pending
- 2020-01-06 AR ARP200100028A patent/AR117770A1/es unknown
- 2020-01-06 MX MX2021008147A patent/MX2021008147A/es unknown
- 2020-01-06 KR KR1020217024431A patent/KR20210113265A/ko active Pending
- 2020-01-06 AU AU2020206672A patent/AU2020206672B2/en active Active
- 2020-01-06 CA CA3125529A patent/CA3125529A1/en active Pending
- 2020-01-06 BR BR112021012294-0A patent/BR112021012294A2/pt unknown
- 2020-01-06 US US17/418,458 patent/US20220089667A1/en active Pending
-
2021
- 2021-07-05 IL IL284633A patent/IL284633A/en unknown
- 2021-07-05 CL CL2021001779A patent/CL2021001779A1/es unknown
-
2024
- 2024-10-22 JP JP2024185692A patent/JP2025013911A/ja active Pending
-
2025
- 2025-12-19 AU AU2025283608A patent/AU2025283608A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022516557A5 (https=) | ||
| JP2023532904A5 (https=) | ||
| Chen et al. | Bispecific antibodies in cancer immunotherapy | |
| JP7809680B2 (ja) | 癌処置のための多重特異性結合タンパク質 | |
| JP5851419B2 (ja) | ヘテロダイマー結合タンパク質およびその使用 | |
| Weidle et al. | Tumor-antigen–binding bispecific antibodies for cancer treatment | |
| US11952421B2 (en) | Bispecific antibodies against CD3EPSILON and ROR1 | |
| JP6702893B2 (ja) | 多重特異的抗原結合タンパク質 | |
| FI3749346T3 (fi) | Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät | |
| US20220089722A1 (en) | Heterodimeric fusion protein | |
| CN115066274A (zh) | 三价结合分子 | |
| WO2023051727A1 (zh) | 结合cd3的抗体及其用途 | |
| CA3125120A1 (en) | Antibody fusion protein, preparation method therefor and application thereof | |
| JP2024534468A5 (https=) | ||
| JP2025504795A5 (https=) | ||
| CN115836084A (zh) | 多特异性免疫调节剂 | |
| Spasevska | An outlook on bispecific antibodies: Methods of production and therapeutic benefits | |
| JP2024521701A (ja) | 抗ｃｄ１３７抗体及びその使用方法 | |
| Brinkmann et al. | The making of multispecific immunoglobulins–a clinical perspective | |
| RU2021123226A (ru) | Полипептиды, содержащие модифицированный полипептид il-2, и их применения | |
| US20250376524A1 (en) | Tetravalent multispecific binding molecules and methods of use thereof | |
| WO2025201240A1 (en) | Antibodies targeting cd3, cd28, and pd-l1 and uses thereof | |
| WO2023199927A1 (ja) | がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｔｓｐａｎ８－抗ｃｄ３二重特異性抗体の使用 | |
| WO2025167357A1 (zh) | Cd80/taa融合蛋白相关的肿瘤靶向、t细胞激活分子形式及其应用 | |
| WO2023219121A1 (ja) | 抗ｔａａ－抗ｃｄ３多重特異性抗体 |